EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Memantine: updates from the past decade and implications for future novel therapeutic applications

Wojciech Danysz, Niels Hansen, Jens Wiltfang, Johannes Kornhuber, Astrid Scheschonka, Andreas Gravius

Journal of Neural Transmission · 2026-07 · 133 (7) · 1205-1277

DOI: 10.1007/s00702-025-03017-8 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Neural Transmission, online erschienen am 24.10.2025. Verfasst von Wojciech Danysz und 5 weiteren Autor:innen. Beteiligte Einrichtung: Merz Therapeutics GmbH, Eckenheimer Landstraße 100, 60318, Frankfurt am Main, Germany. Wojciech.Danysz@merz.de. Hauptthemen laut MEDLINE: Memantine, Alzheimer Disease, Excitatory Amino Acid Antagonists. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 444 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This review provides an update on advances during the past decade in our knowledge of the pharmacology and clinical use of memantine. It covers aspects related to preclinical research, such as new findings about the mechanism of action, and the efficacy of memantine in animal models of various diseases beyond dementia. In particular, new emerging indications since the publication of our latest review almost a decade ago were investigated. Where possible, preclinical findings were reinforced by data obtained in clinical studies in patients with Alzheimer's disease, as well as in other indications reported by researchers who initiated off-label studies. This comprehensive narrative review demonstrates that memantine continues to show robust efficacy in its primary indication of Alzheimer's disease. However, while numerous potential new indications have emerged from preclinical studies, only a limited number show sufficient evidence to warrant further clinical investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MemantineAlzheimer DiseaseExcitatory Amino Acid AntagonistsHumansAnimals

Stichwörter der Autor:innen

AlzheimerEfficacyMechanism of actionMemantineNew indicationsPharmacologyUpdate

Substanzen

MemantineExcitatory Amino Acid Antagonists

Autor:innen und Institutionen

  • Merz Therapeutics GmbH, Eckenheimer Landstraße 100, 60318, Frankfurt am Main, Germany. Wojciech.Danysz@merz.de.
  • Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, Von-Siebold-Str. 5, 37075, Göttingen, Germany.
  • Department of Psychiatry and Psychotherapy, Friedrich-Alexander-University Erlangen, Schwabachanlage 6, 91054, Erlangen, Germany.
  • Merz Therapeutics GmbH, Eckenheimer Landstraße 100, 60318, Frankfurt am Main, Germany.

Zitieren

APA

Danysz, W., Hansen, N., Wiltfang, J., Kornhuber, J., Scheschonka, A., & Gravius, A. (2026). Memantine: updates from the past decade and implications for future novel therapeutic applications. Journal of Neural Transmission, 133(7), 1205-1277. https://doi.org/10.1007/s00702-025-03017-8

Vancouver

Danysz W, Hansen N, Wiltfang J, Kornhuber J, Scheschonka A, Gravius A. Memantine: updates from the past decade and implications for future novel therapeutic applications. Journal of Neural Transmission. 2026;133(7):1205-1277. doi:10.1007/s00702-025-03017-8

BibTeX
@article{Danysz2026,
  author = {Danysz, Wojciech and Hansen, Niels and Wiltfang, Jens and Kornhuber, Johannes and Scheschonka, Astrid and Gravius, Andreas},
  title = {Memantine: updates from the past decade and implications for future novel therapeutic applications},
  journal = {Journal of Neural Transmission},
  year = {2026},
  volume = {133},
  number = {7},
  pages = {1205--1277},
  doi = {10.1007/s00702-025-03017-8}
}
Kostenlos starten →